16:13:27 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Biosergen är verksamma inom bioteknik. Bolaget är specialiserade inom forskning och utveckling av diverse läkemedel. Produktportföljen inkluderar exempelvis bolagets produkt BSG005, ett svampdödande läkemedel i klinisk fas. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs i Norge. Biosergen grundades år 2004 och har sitt huvudkontor i Solna.

Kalender

2022-11-30 Kvartalsrapport 2022-Q3
2022-08-31 Kvartalsrapport 2022-Q2
2022-06-30 Årsstämma 2022
2022-05-31 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning BIOSGN 0.00 SEK
2022-03-31 Bokslutskommuniké 2021
2021-11-30 Kvartalsrapport 2021-Q3
2022-05-13 10:58:14

May 13, 2022: Biosegen AB ("Biosergen" or the "Company") today announced that the Safety Review Committee found no safety issues in the first 6-volunteer cohort in the Single Ascending Dose part of BSG005's phase I trial. The trial will escalate to the next dose level as planned.

BSG005 is Biosergen's lead development compound. It is an anti-fungal molecule from the group of polyene macrolides known for their broad anti-fungal and fungicidal effect, including on resistant and difficult-to-treat fungal strains.

The clinical phase I trial is a double-blinded, placebo-controlled study in up to 72 healthy male volunteers (subjects). The trial is designed as a Single Ascending Dose (SAD) study followed by a Multiple Ascending Dose (MAD) study to investigate the safety and tolerability of BSG005. It is conducted in the Nucleus Network phase I Unit in Melbourne, Australia.

Biosergen's CEO Peder M. Andersen comments:
"We are off to a good start. If this trial continuous to show that BSG005 is well tolerated and that we can achieve what we believe are thereapeutic concentrations of the drug in the bloodstream of the subjects at safe doses, Biosergen will have taken a very significant step forward. I look forward to keeping you updated as the results come in."

Phase I study design
The phase I study is divided into two sequential parts:

  • The Single Ascending Dose (SAD) part of the trial will enrol up to 42 subjects divided into 7 groups of 6 subjects each. In each cohort, 4 subjects receive a single dose of BSG005, whereas 2 receive placebo. Each subject participates in just one treatment cohort, and no subject receives more than one dose of BSG005 (or placebo as the case may be). The dose of BSG005 will be increased for each progressive group if previous dose levels are well tolerated and no safety issues observed. These safety reviews are performed by the  study's Safety Review Committee after each dose level.
The Multiple Ascending Dose (MAD) part of the trial will enroll up to 30 subjects divided into 5 groups of 6 subjects each. In this part of the trial, the subjects receive increasing doses of BSG005 over a 7 day period. While the objectives of the Single Ascending Dose trial above is to establish a basic understanding of BSG005's pharmacokinetics and maximum tolerated dose when given as a single dose, the Multiple  Ascending Dose part of the trial aims to establish what dose level of BSG005 is required to obtain a steady, clinically relevant concentration of the drug in the subject's blood stream. Biosergen expects to be able to publish data from this part of the trial in Q4 2022.